The REgistry of Very Early Estrogen and AnovuLation

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-40
SponsorMayo Clinic

About this trial

The purpose of this study is to to build a registry of women with early estrogen loss due to Functional Hypothalamic Amenorrhea (FHA) to understand the prevalence, racial and ethnic diversity of this condition.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Estradiol: < 50pg/mL

LH: < 10 IU/mL

FSH: < 10 IU

Testosterone: 2 - 45 ng/dL

Disqualifiers

Parturition/lactating in the last 6-12 months

Lack of consent

Trial population

The study subjects are women aged 18-40 years old with a diagnosis of Functional Hypothalamic Amenorrhea (FHA) or lab results that are within the inclusion criteria. To ensure accurate case ascertainment before enrollment into the study, volunteers must have a diagnosis of FHA from a provider with previously performed lab tests, which will be reviewed and adjudicated by a women's health expert to confirm a diagnosis of FHA. If the potential participant doesn't have access or cannot obtain the required lab results, they can contact the study team to receive an at-home finger-stick hormone test (U.S. Specialty Labs) paid for by the study.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)

    Other intervention

    Subjects will complete the ASA food diary for 2 weekdays and 1 weekend day

  • REVEAL Questionnaire

    Other intervention

    Subjects will complete the REVEAL questionnaire form. This form includes questions about current and past medical history, including reproductive history, lifestyle specifics, and assessment of current health status.

Treatment groups

100,000 Participants
are divided into 1 treatment group
Group A: Women with > 3 months amenorrhea2 interventions

Trial outcomes

Primary outcomes

1

Study Participants

Establish and maintain a comprehensive registry of patients diagnosed with Functional Hypothalamic Amenorrhea (FHA). This registry will include detailed demographic information, clinical data, and longitudinal follow-up to track the prevalence, underlying causes, risk factors, and prognosis of FHA. It will also facilitate the collection of data on racial and ethnic disparities, lifestyle factors, psychological stressors, hormonal imbalances, and the impact of various treatment interventions on long-term health outcomes collected through questionnaires done at baseline and yearly.

Time frame
5 years

Secondary outcomes

1

Assessing the Impact of Amenorrhea on Women's Health: Symptoms, Care Experiences, and Work Productivity

Improve understanding of women's overall experience of Functional Hypothalamic Amenorrhea (FHA) by documenting the types of care received, frequency and quality of healthcare interactions, and patient satisfaction with the care provided. This includes detailed assessments of specific treatments or therapies received, the involvement of multidisciplinary care approaches, and the extent of follow-up care. Additionally, to quantify the impact of FHA on lost work productivity, including the number of workdays missed, impact on work performance, and economic burden associated with amenorrhea-related issues, measured at baseline and then yearly using questionnaires.

Time frame
5 years
2

Impact of Social, Early Life, and Pregnancy Factors on Functional Hypothalamic Amenorrhea

Enhance the understanding of how social determinants of health-such as socioeconomic status, education, access to healthcare, and community environment-contribute to the development of Functional Hypothalamic Amenorrhea (FHA). Additionally, the study will explore the impact of childhood adversity, including exposure to trauma, abuse, neglect, or chronic stress, on the likelihood of developing FHA. The relationship between pregnancy complications, such as preterm birth, miscarriage, or gestational conditions, and the onset of FHA will also be analyzed. Data will be collected through baseline and annual questionnaires throughout the study, providing a comprehensive understanding of these factors' roles in the development of FHA.

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.